MYCN deregulation as a potential target for novel therapies in rhabdomyosarcoma (Q36381278)

13 August 2017

1 reference

title

MYCN deregulation as a potential target for novel therapies in rhabdomyosarcoma (English)

1 reference

13 August 2017

1 reference

Daniel A Morgenstern

1 reference

13 August 2017

John Anderson

series ordinal

1 reference

13 August 2017

publication date

1 February 2006

1 reference

Expert Review of Anticancer Therapy

13 August 2017

published in

1 reference

13 August 2017

1 reference

13 August 2017

1 reference

13 August 2017

page(s)

217-224

1 reference

Molecular pathogenesis of rhabdomyosarcoma

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.217

PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.217

The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.217

Coordinated oncogenic transformation and inhibition of host immune responses by the PAX3-FKHR fusion oncoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.217

In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.217

Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.217

Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.217

Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.217

Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.217

Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.217

Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.217

Low molecular weight inhibitors of Myc-Max interaction and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.217

Targeted expression of MYCN causes neuroblastoma in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.217

Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.217

Part I: Vaccines for solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.217

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.217

Anti-gene peptide nucleic acid specifically inhibits MYCN expression in human neuroblastoma cells leading to cell growth inhibition and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.217

21 January 2018

Identifiers

DOI

10.1586/14737140.6.2.217

1 reference

13 August 2017

1 reference